Medica is pleased to announce that Dr Junaid Bajwa will join the Board of Medica as Non-Executive Director and Chair of the Clinical Risk Committee.

Dr Junaid Bajwa will join the Board of Medica as a Non-Executive Director and Chair of the Clinical and Risk Committee on the 1st April 2021.

Junaid is a highly skilled individual who brings a wealth of experience with him in his new role at Medica. Junaid is a practicing physician in the NHS and currently occupies the roles of Chief Medical Scientist at Microsoft Research, and as a Non-Executive Director at University College London Hospitals NHS Foundation Trust.

He was previously the Global Lead for Strategic Alliances and Solutions for the Global Digital Centre of Excellence at Merck Sharp & Dohme (Merck & Co), where he helped shape their global digital strategy. Junaid also has experience in the academic world where he is a Clinical Associate Professor at University College London (UCL), and a Visiting Scientist at the Harvard School of Public Health.

Over the past 15 years, Junaid has worked across primary care, secondary care, and public health settings in addition to acting as a payer, and policy maker within the UK, where he specialised in informatics, digital transformation, and leadership. He has also acted as a consultant for health care systems across the US, Australia, New Zealand, Singapore, the Middle East, and Europe.

Roy Davis, Chairman of Medica, said

“We are delighted to have someone of Junaid’s experience join the Board. His clinical expertise coupled with his digital healthcare and commercial experience will be of enormous benefit to Medica as we continue to expand our technological and telemedicine service offerings internationally. I very much look forward to working with him.”

Commenting on his appointment, Dr Junaid Bajwa added

“I am very pleased to be joining the board of an exciting and rapidly-growing company. Medica has a compelling strategy in place which speaks directly to my clinical and digital healthcare skill set. I am looking forward to engaging with the Board and the management team and using my expertise to help implement this strategy.”